Cantor Fitzgerald set a $10.00 price objective on Amarin (NASDAQ:AMRN) in a research note released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on AMRN. BidaskClub downgraded shares of Amarin from a sell rating to a strong sell rating in a research report on Thursday, August 24th. ValuEngine downgraded shares of Amarin from a hold rating to a sell rating in a research report on Thursday, November 16th. HC Wainwright restated a buy rating and set a $10.00 price objective on shares of Amarin in a research report on Thursday, November 2nd. Zacks Investment Research downgraded shares of Amarin from a buy rating to a hold rating in a research report on Friday, November 3rd. Finally, Jefferies Group restated a buy rating on shares of Amarin in a research report on Wednesday, October 11th. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Amarin presently has a consensus rating of Hold and a consensus price target of $7.75.

Amarin (NASDAQ AMRN) traded up $0.05 on Tuesday, reaching $3.59. 1,987,200 shares of the company’s stock traded hands, compared to its average volume of 1,730,763. Amarin has a fifty-two week low of $2.81 and a fifty-two week high of $4.47. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. The firm’s revenue for the quarter was up 45.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.08) earnings per share. equities analysts anticipate that Amarin will post -0.22 EPS for the current year.

In other Amarin news, insider Steven B. Ketchum sold 63,479 shares of Amarin stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $3.48, for a total value of $220,906.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John F. Thero purchased 10,000 shares of Amarin stock in a transaction on Thursday, November 30th. The stock was bought at an average price of $3.24 per share, for a total transaction of $32,400.00. The disclosure for this purchase can be found here. 3.72% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRN. Westside Investment Management Inc. increased its holdings in Amarin by 1.1% in the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Amarin by 15.2% in the 2nd quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 5,000 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Amarin in the 3rd quarter valued at $226,000. Stevens Capital Management LP bought a new stake in Amarin in the 3rd quarter valued at $229,000. Finally, TD Asset Management Inc. bought a new stake in Amarin in the 3rd quarter valued at $285,000. Institutional investors own 40.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/amarin-amrn-given-a-10-00-price-target-by-cantor-fitzgerald-analysts/1774672.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.